Cadrenal Therapeutics (CVKD) Set to Release Earnings on Monday

Cadrenal Therapeutics (NASDAQ:CVKD) will likely be announcing its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of ($0.91) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its earnings results on Thursday, August 13th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.28. On average, analysts expect Cadrenal Therapeutics to post ($3.86) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Cadrenal Therapeutics Stock Performance

Shares of CVKD opened at $1.01 on Monday. The company’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $3.97. The stock has a market capitalization of $3.60 million, a PE ratio of -0.20 and a beta of 1.94. Cadrenal Therapeutics has a 1 year low of $0.82 and a 1 year high of $13.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices.

Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism.